<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2612">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04787510</url>
  </required_header>
  <id_info>
    <org_study_id>895/23-12-2020</org_study_id>
    <nct_id>NCT04787510</nct_id>
  </id_info>
  <brief_title>COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection</brief_title>
  <official_title>COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ioannina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>INTERNAL MEDICINE DEPARTMENT, 1ST WARD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ioannina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effect of Covid-19 disease in clotting factors levels in hospitalized patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Effect of Covid-19 disease in clotting factors levels in hospitalized patients positive for&#xD;
      sars-cov2 infection.&#xD;
&#xD;
      Association between clotting factors levels and disease severity,morbidity and mortality in&#xD;
      these patients.&#xD;
&#xD;
      Effect of anticoagulant therapy in the clotting factors' levels in these patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2020</start_date>
  <completion_date type="Anticipated">June 23, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 23, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>EFFECT OF COVID-19 DISEASE IN CLOTTING FACTORS</measure>
    <time_frame>6 MONTHS</time_frame>
    <description>leves of cloting factors before and after treatment with LMWH</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>SARS-COV2 Infection</condition>
  <condition>COVID-19 Disease</condition>
  <condition>Hospitalized Patients</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low molecular weight Heparin as standard of care treatment</intervention_name>
    <description>STANDARD OF CARE</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      PLASMA AND CLOTTING FACTORS&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        ALL ELIGIBLE PATIENTS AS DEFINED BY CRITERIA&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AGE&gt; 18&#xD;
&#xD;
          -  SINGED INFORMED CONSENT FORM&#xD;
&#xD;
          -  POSITIVE PCR TEST FOR SARS-COV2 INFECTION&#xD;
&#xD;
          -  FINDINGS IN CXR OR CT OF THE LUNGS CONSISTENT WITH INFECTION OF LOWER RESPIRATORY&#xD;
             TRACT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  AGE&lt;18&#xD;
&#xD;
          -  DENIAL TO PROVIDE INFORMED CONSENT FORM&#xD;
&#xD;
          -  HISTORY OF MALIGNANCY&#xD;
&#xD;
          -  PRIOR USE OF ANTICOAGULANT THERAPY&#xD;
&#xD;
          -  PRIOR USE OF STEROIDS LONGER THAN 14 DAYS&#xD;
&#xD;
          -  LACTATION-PREGNANCY&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HARALAMPOS MILIONIS, PROFESSOR</last_name>
    <role>Principal Investigator</role>
    <affiliation>University General Hospital of Ioannina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ANGELOS LIONTOS, CONSULTANT</last_name>
    <phone>6936626792</phone>
    <email>angelosliontos@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ELEFTHERIOS KLOURAS, CONSULTANT</last_name>
    <phone>2651099924</phone>
    <email>elklouras@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University General Hospital of Ioannina</name>
      <address>
        <city>Io√°nnina</city>
        <state>Epirus</state>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ANGELOS LIONTOS, CONSULTANT</last_name>
      <phone>6936626792</phone>
      <email>angelosliontos@gmail.com</email>
    </contact>
    <investigator>
      <last_name>HARALAMPOS MILIONIS, PROFESSOR</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>MARIA KOSMIDOU, ASSIST, PR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>ANGELOS LIONTOS, CONSULTANT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>EYAGGELOS LYMPEROPOULOS, ASSOC. PR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>CHRISTINA TSAOUSI, DPT DIRECTOR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>EYAGGELIA PAPAPETROU, CONSULTANT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>IRO RAPTI, CONSULTANT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>FOTIOS BARKAS, CONSULTANT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>ELEFTHERIOS KLOURAS, RESIDENT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>SEMPASTIEN DEKOUAN-FILIPPAS, RESIDENT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Ioannina</investigator_affiliation>
    <investigator_full_name>Liontos Angelos</investigator_full_name>
    <investigator_title>CONSULTANT OF INTERNAL MEDICINE</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

